NRx Retained Earnings from 2010 to 2024

NRXPW Stock

USD 0.05 0 3.73%

NRx Pharmaceuticals Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2024. Retained Earnings is the cumulative amount of net income that NRx Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2017-09-30

Previous Quarter

-267.6 M

Current Value

-269.2 M

Quarterly Volatility

113.9 M

Covid

Check NRx Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NRx Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 K, Interest Expense of 114 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. NRx financial statements analysis is a perfect complement when working with NRx Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of NRx Pharmaceuticals Correlation against competitors.

For more information on how to buy NRx Stock please use our How to Invest in NRx Pharmaceuticals guide.

Latest NRx Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of NRx Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. NRx Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NRx Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (253.15 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

NRx Retained Earnings Regression Statistics

	Arithmetic Mean	(66,041,890)
	Geometric Mean	1,294,106
	Coefficient Of Variation	(155.67)
	Mean Deviation	87,987,893
	Median	(105,033)
	Standard Deviation	102,804,141
	Sample Variance	10568.7T
	Range	253.5M
	R-Value	(0.83)
	Mean Square Error	3613.7T
	R-Squared	0.68
	Significance	0.0001
	Slope	(18,990,984)
	Total Sum of Squares	147961.7T

NRx Retained Earnings History

	2024	-240.5 M
	2023	-253.1 M
	2022	-223.1 M
	2021	-183.2 M
	2020	-90.2 M
	2019	369.5 K
	2018	-38.9 K

Other Fundumenentals of NRx Pharmaceuticals

Retained Earnings Total Equity

NRx Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Net Tangible Assets	Long Term Debt	Net Receivables	Capital Surpluse	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Current Deferred Revenue
Total Assets		0.98	0.08	0.83	-0.88	0.97	-0.84	-0.49	0.97	0.58	-0.66	0.7	0.58	-0.62	-0.64	-0.71	-0.58	-0.64	0.58
Total Stockholder Equity	0.98		0.09	0.79	-0.87	0.94	-0.92	-0.46	0.94	0.51	-0.6	0.63	0.51	-0.57	-0.59	-0.64	-0.53	-0.59	0.51
Net Debt	0.08	0.09		0.27	-0.33	0.31	-0.11	-0.82	0.31	-0.33	-0.44	0.4	-0.33	-0.59	0.08	-0.08	-0.69	0.08	-0.33
Retained Earnings	0.83	0.79	0.27		-0.88	0.9	-0.61	-0.74	0.89	0.66	-0.93	0.96	0.66	-0.91	-0.85	-0.93	-0.86	-0.85	0.66
Accounts Payable	-0.88	-0.87	-0.33	-0.88		-0.91	0.76	0.64	-0.9	-0.47	0.83	-0.8	-0.47	0.75	0.66	0.8	0.73	0.66	-0.47
Short Term Investments	0.97	0.94	0.31	0.9	-0.91		-0.79	-0.7	1.0	0.5	-0.78	0.81	0.5	-0.79	-0.66	-0.75	-0.76	-0.66	0.5
Total Liab	-0.84	-0.92	-0.11	-0.61	0.76	-0.79		0.35	-0.79	-0.27	0.4	-0.41	-0.27	0.38	0.4	0.41	0.36	0.4	-0.27
Total Current Assets	-0.49	-0.46	-0.82	-0.74	0.64	-0.7	0.35		-0.7	-0.15	0.82	-0.83	-0.15	0.94	0.45	0.57	0.97	0.45	-0.15
Common Stock	0.97	0.94	0.31	0.89	-0.9	1.0	-0.79	-0.7		0.49	-0.78	0.81	0.49	-0.78	-0.65	-0.74	-0.75	-0.65	0.49
Net Tangible Assets	0.58	0.51	-0.33	0.66	-0.47	0.5	-0.27	-0.15	0.49		-0.45	0.61	1.0	-0.42	-0.59	-0.7	-0.33	-0.59	1.0
Long Term Debt	-0.66	-0.6	-0.44	-0.93	0.83	-0.78	0.4	0.82	-0.78	-0.45		-0.96	-0.45	0.95	0.83	0.92	0.93	0.83	-0.45
Net Receivables	0.7	0.63	0.4	0.96	-0.8	0.81	-0.41	-0.83	0.81	0.61	-0.96		0.61	-0.97	-0.81	-0.92	-0.94	-0.81	0.61
Capital Surpluse	0.58	0.51	-0.33	0.66	-0.47	0.5	-0.27	-0.15	0.49	1.0	-0.45	0.61		-0.42	-0.59	-0.7	-0.33	-0.59	1.0
Net Invested Capital	-0.62	-0.57	-0.59	-0.91	0.75	-0.79	0.38	0.94	-0.78	-0.42	0.95	-0.97	-0.42		0.71	0.81	0.99	0.71	-0.42
Short Long Term Debt	-0.64	-0.59	0.08	-0.85	0.66	-0.66	0.4	0.45	-0.65	-0.59	0.83	-0.81	-0.59	0.71		0.93	0.63	1.0	-0.59
Capital Stock	-0.71	-0.64	-0.08	-0.93	0.8	-0.75	0.41	0.57	-0.74	-0.7	0.92	-0.92	-0.7	0.81	0.93		0.75	0.93	-0.7
Net Working Capital	-0.58	-0.53	-0.69	-0.86	0.73	-0.76	0.36	0.97	-0.75	-0.33	0.93	-0.94	-0.33	0.99	0.63	0.75		0.63	-0.33
Short Term Debt	-0.64	-0.59	0.08	-0.85	0.66	-0.66	0.4	0.45	-0.65	-0.59	0.83	-0.81	-0.59	0.71	1.0	0.93	0.63		-0.59
Current Deferred Revenue	0.58	0.51	-0.33	0.66	-0.47	0.5	-0.27	-0.15	0.49	1.0	-0.45	0.61	1.0	-0.42	-0.59	-0.7	-0.33	-0.59

Click cells to compare fundamentals

About NRx Pharmaceuticals Financial Statements

NRx Pharmaceuticals investors use historical fundamental indicators, such as NRx Pharmaceuticals' Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NRx Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-253.1 M	-240.5 M
Retained Earnings Total Equity	-648 K	-680.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for NRx Stock Analysis

When running NRx Pharmaceuticals' price analysis, check to measure NRx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRx Pharmaceuticals is operating at the current time. Most of NRx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRx Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC